Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01396200 · ClinicalTrials.gov registry record · Early Phase 1
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01396200: Completed Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01396200 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01396200, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility of giving (i) rapamycin or (ii) hydroxychloroquine (HCQ), with standard doses of infusional cyclophosphamide and pulse dexamethasone (cy/dex) for patients with relapsed/refractory multiple myeloma, as well as the feasibility of obtaining multiple blood and bone marrow samples during treatment to assess the pharmacodynamic effects of the treatment.
Primary Outcome
The feasibility of administering rapamycin and hydroxychloroquine (HCQ), with standard doses of infusional cyclophosphamide and pulse dexamethasone (cy/dex) for patients with relapsed/refractory multiple myeloma.
Interventions
- DRUG Rapamycin
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-10 |
| Phase | Early Phase 1 |
What the finished NCT01396200 record still lists
NCT01396200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Rapamycin is the first listed.
NCT01396200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01396200 about?
NCT01396200 is a clinical study titled "Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine". The purpose of this study is to determine the feasibility of giving (i) rapamycin or (ii) hydroxychloroquine (HCQ), with standard doses of infusional cyclophosphamide and pulse dexamethasone (cy/dex) for patients with relapsed/refractory multiple myeloma, as well as the feasibility of obtaining mult...
What is the current status of trial NCT01396200?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2011-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01396200?
The interventions under investigation include: Rapamycin (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01396200?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01396200's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia